Compositions for the treatment of skin conditions

Abstract

Described herein are methods and compositions for the treatment of skin conditions associated the dysbiosis. Further described herein is the use of metabolites for treatment of dysregulated microbiota in a subject. Such metabolites can be produced by microorganisms present in a higher abundance in the skin of healthy subjects as compared to the skin of a subject having dysbiosis of the skin. In addition, compositions and methods provided herein describe the use of metabolites as part of a combination therapy.

What is claimed is: 
     
         1 . A method for treatment of a skin condition associated with inflammation or barrier disruption, comprising administering to a subject in need thereof:
 a. a metabolite; and   b. at least one strain of a live, purified gram-negative bacteria, wherein the administering provides for reduction of a skin condition associated with inflammation or barrier disruption in the subject.   
     
     
         2 . The method of  claim 1 , wherein the metabolite is N4-acetylaminobutanal, 5-ethylpentadecane-2,4-dione, ricinoleic acid methyl ester, trenbolone acetate, or N-(2-hydroxyethyl)-11(12)-epoxy-5Z,8Z,14Z-eicosatrienamide. 
     
     
         3 . The method of  claim 1 , wherein the metabolite is a lipid. 
     
     
         4 . The method of  claim 3 , wherein the lipid is at least one phosphatidylethanolamine. 
     
     
         5 . The method of  claim 3 , wherein the lipid comprises phosphatidylethanolamine 36:2, phosphatidylcholine 37:0, phosphatidylcholine 37:2, phosphatidylcholine 38:2, phosphatidylcholine(18:2(9Z,12Z)/18:0), phosphatidylethanolamine 14:0/20:1, phosphatidylethanolamine 22:1/14:1, or 8-keto palmitic acid. 
     
     
         6 . The method of  claim 1 , wherein the metabolite is a peptide. 
     
     
         7 . The method of  claim 6 , wherein the peptide comprises Tyr-Leu-Arg. 
     
     
         8 . The method of  claim 1 , wherein the metabolite is a sugar. 
     
     
         9 . The method of  claim 8 , wherein the sugar comprises maltopentaose. 
     
     
         10 . The method of  claim 1 , wherein the metabolite is a nucleotide. 
     
     
         11 . The method of  claim 10 , wherein the nucleotide comprises 2′-deoxyguanosine 5′-monophosphate. 
     
     
         12 . The method of  claim 1 , wherein the metabolite is in a topical dosage form. 
     
     
         13 . The method of  claim 12 , wherein the topical dosage form is a liquid, cream, gel, or foam. 
     
     
         14 . The method of  claim 1 , wherein the live, purified gram negative bacteria comprises a species is of the genus  Pseudomonas, Pantoea, Moraxella, Roseomonas,  or  Vitreoscilla.    
     
     
         15 . The method of  claim 1 , wherein the live, purified gram negative bacteria comprises  Roseomonas mucosa, Pseudomonas aeruginosa,  or  Moraxella osloensis.    
     
     
         16 . The method of  claim 1 , wherein the live, purified gram negative bacteria is  Roseomonas mucosa.    
     
     
         17 . The method of  claim 1 , wherein the live, purified gram negative bacteria is in a topical dosage form. 
     
     
         18 . The method of  claim 17 , wherein the topical dosage form is a liquid, cream, gel, or foam. 
     
     
         19 . The method of  claim 1 , wherein the metabolite and the live, purified gram negative bacteria are concurrently administered. 
     
     
         20 . The method of  claim 1 , wherein the metabolite and the live, purified gram negative bacteria are present together in a pharmaceutical composition. 
     
     
         21 . The method of  claim 1 , wherein the metabolite and the live, purified gram negative bacteria are present in separate pharmaceutical compositions. 
     
     
         22 . The method of  claim 1 , wherein the skin condition associated with inflammation or barrier disruption is eczema, allergic eczema, flexural eczema, infantile eczema, nummular eczema, discoid lupus, prurigo Besnier, psoriasis, vitiligo, dermatitis, atopic dermatitis, perioral dermatitis, neurodermatitis, seborrheic dermatitis, rosacea, or acne.